The mechanism of miR-16-5p protection on LPS-induced A549 cell injury by targeting CXCR3
Source abstract
Abstract
OBJECTIVE: To study the effect of miR-16-5p on lung cancer cell injury and apoptosis, and its mechanism. METHODS: LPS induced lung cancer cell A549 injury; qRT-PCR method was applied to detect the expression of miR-16-5p and CXCR3 in A549 cells. Con (without LPS treatment), LPS + miR-NC group (transfected negative control samples), LPS + miR-16-5p group (transfected miR-16-5p mimics); LPS + si-NC group (transfected negative control samples), LPS + si-CXCR3 group (transfected si-CXCR3); LPS + miR-16-5p + pcDNA3.1 group (co-transfected miR-16-5p mimics and pcDNA3.1), LPS + miR-16-5p + pcDNA3.1-CXCR3 group (co-transfected miR-16-5p mimics and pcDNA3.1-CXCR3) were transfected into A549 cells by liposome method. Western blot was used to detect protein expression of CXCR3, IL-6 and TNF-α in A549 cells; apoptosis of A549 cells was detected by flow cytometry. RESULTS: Compared with the control group, the expression of miR-16-5p mRNA was significantly decreased in A549 cells in LPS group, and the mRNA and protein expression of CXCR3 were significantly increased (p < .05). Overexpression of miR-16-5p and knockdown of CXCR3 both can down-regulated protein expression of IL-6 and TNF-α, and up-regulated apoptosis in LPS-induced A549 cell; CXCR3 is a target of miR-16-5p. Overexpression of CXCR3 rescued the protective effect of miR-16-5p on LPS-induced A549 cell injury. CONCLUSION: miR-16-5p can protect LPS-induced A549 cell injury, and its mechanism may be related to the targeted regulation of CXCR3, which could provide a new target for targeted therapy of lung cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Chemokine receptors and signaling · Cytokine Signaling Pathways and Interactions · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Clinical Medicine, Ningxia Medical University
Ningxia Institute For Human Stem Cell Research, General Hospital of Ningxia Medical University
Department of Pathology, The Sixth People’s Hospital of Yancheng City
Department of Laboratory Medicine, Tongji Hospital of Tongji University
Funding
National Natural Science Foundation of China · Medical Science and Technology Development Program of Yancheng City
References (20)
Show source-provided references
1. 10.1373/clinchem.2015.24119010.1373/clinchem.2015.241190 ↗
2. 10.7150/thno.1030510.7150/thno.10305 ↗
3. Yoshie O. Chemokines and chemokine receptors. Nihon Rinsho. 2012;70:212–217.
4. 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W ↗
5. Qiu MY, Li JW, Zheng M. The chemokine receptors CXCR4 and CXCR7 in cancer. China Oncol. 2010;20:222–226.
6. 10.1186/1476-4598-11-310.1186/1476-4598-11-3 ↗
7. Li L, Chen J, Lu ZH, et al. Significance of chemokine receptor CXCR3 expression in breast cancer. Zhonghua Bing li Xue za Zhi. 2011;40:85–88.
8. Li K, Zhu Z, Luo J, et al. Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer. Intern J Clin Exp Path. 2015;8:14725–14732.
9. 10.3892/mmr.2017.694910.3892/mmr.2017.6949 ↗
10. 10.7150/ijms.2734110.7150/ijms.27341 ↗
11. 10.1038/s41598-018-35139-310.1038/s41598-018-35139-3 ↗
12. 10.1089/dna.2017.404010.1089/dna.2017.4040 ↗
13. 10.1038/s41419-018-0738-z10.1038/s41419-018-0738-z ↗
14. Gu Y, Wang XD, Lu JJ, et al. Effect of mir-16 on proliferation and apoptosis in human A549 lung adenocarcinoma cells. Int J Clin Exp Med. 2015;8:3227–3233.
15. 10.1016/j.febslet.2013.08.01010.1016/j.febslet.2013.08.010 ↗
16. 10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S10.1002/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S ↗
17. 10.1038/icb.2010.15810.1038/icb.2010.158 ↗
18. 10.21037/jtd.2017.03.6110.21037/jtd.2017.03.61 ↗
19. 10.4049/jimmunol.080334010.4049/jimmunol.0803340 ↗
20. 10.1158/1078-0432.CCR-10-334610.1158/1078-0432.CCR-10-3346 ↗